CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes

Area of Science:

• Immunology
• Genetics
• Biotechnology

Background:

• Human platelet alloantigens (HPAs) are glycoproteins on platelets, with variations caused by gene polymorphisms.
• Antibodies against HPAs cause alloimmune bleeding disorders like fetal/neonatal alloimmune thrombocytopenia.
• The HPA-1a/HPA-1b system is common in white populations, with a Leu33Pro polymorphism in integrin β3 subunit.

Purpose of the Study:

• To genetically engineer cells to express the HPA-1b alloantigen using CRISPR/Cas9 technology.
• To address the scarcity of HPA-1b platelets for transfusion and diagnostic purposes.
• To explore the potential of gene editing for producing custom platelets.

Main Methods:

• CRISPR/Cas9 gene editing was applied to megakaryocyte-like DAMI cells and induced pluripotent stem cells (iPSCs).
• Cells were edited to express the Pro33 allotype, corresponding to HPA-1b.
• Expression of the HPA-1b epitope was confirmed using restriction enzyme digestion, DNA sequencing, and western blot analysis.

Main Results:

• Engineered DAMI cells and iPSCs successfully expressed the HPA-1b (Pl(A2)) alloantigenic epitope.
• Confirmation of the allotype change was achieved through multiple validated methods.
• The study demonstrated the feasibility of targeted gene editing for HPA modification.

Conclusions:

• CRISPR/Cas9 technology can be effectively used to generate specific human platelet alloantigens.
• This approach holds significant promise for the development of 'designer platelets'.
• Potential applications include improved diagnostic tools and future therapeutic strategies for alloimmune disorders.